share_log

UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy

UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy

瑞银将诺诚健华的目标股价从17.70港元调整至16.20港元,维持买入
MT Newswires ·  2022/08/24 04:21

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发